{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:49:30Z","timestamp":1793191770953,"version":"4.5.0"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emicizumab has been approved for bleeding prophylaxis in patients with haemophilia A (PWHAs) with or without inhibitors. Because of substantial differences between factor VIII (FVIII) and Emicizumab, the \u2018St\u00e4ndige Kommission H\u00e4mophilie\u2019 of the German, Austrian, Swiss Society for Thrombosis and Haemostasis Research (GTH) established a practical guidance for the use of Emicizumab in PWHAs. A systematic literature research was conducted in PubMed. Based on this and on personal experience, this practical guidance has been developed. Each single statement has been discussed among members of the \u2018St\u00e4ndige Kommission H\u00e4mophilie\u2019 and revised accordingly. The final set of recommendations has been approved by all authors analogous to the Delphi method. This practical guidance is provided for physicians treating PWHAs with regard to general aspects, patient education, bleeding treatment, surgery, use of Emicizumab in previously untreated patients (PUPs), patients with newly diagnosed inhibitors and elderly patients. Patients should be treated in expert centres and adequate laboratory tests to monitor Emicizumab levels, FVIII replacement and inhibitors should be available. Early experience of immune tolerance induction protocols integrating Emicizumab is reviewed, and the limited experience in PUPs and very young children is described. So far, no thromboembolic complications have been reported with the concomitant use of FVIII or recombinant activated FVII for bleeding treatment or surgery. Activated prothrombin complex concentrate doses of &gt;100 U\/kg for &gt;24\u2009hours should be avoided whenever possible because of the high risk of thrombosis and\/or thrombotic microangiopathy. In conclusion, this study is designed to support haemophilia physicians using Emicizumab in physicians treating hemophilia and using (PWHAs). With further post-marketing experience and trials, regular updates are necessary.<\/jats:p>","DOI":"10.1055\/a-1127-6476","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T01:37:11Z","timestamp":1593135431000},"page":"561-571","source":"Crossref","is-referenced-by-count":28,"title":["Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A"],"prefix":"10.1055","volume":"40","author":[{"given":"Katharina","family":"Holstein","sequence":"additional","affiliation":[{"name":"Haematology and Clinical Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Albisetti","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Children's Hospital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bidlingmaier","sequence":"additional","affiliation":[{"name":"Centre for Development and Complex Chronic Diseases in Children (iSPZHauner), Department of Paediatrics, Paediatric Haemophilia Centre, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halimeh","sequence":"additional","affiliation":[{"name":"Coagulation Center Rhein-Ruhr, Duisburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heine","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology\/Haematology, Saarland University Hospital, Homburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"Internal Medicine, Angiology and Haemostaseology, Haemophilia Centre, Vivantes Hospital Friedrichshain, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, University Hospital Frankfurt, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Kurnik","sequence":"additional","affiliation":[{"name":"Paediatric Haemophilia Centre, Department of Paediatrics, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Male","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute for Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Streif","sequence":"additional","affiliation":[{"name":"Department of Paediatrics 1, Medical University of Innsbruck (MUI), Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Wermes","sequence":"additional","affiliation":[{"name":"Haemophilia Center, Werlhof-Institute, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Escuriola-Ettingshausen","sequence":"additional","affiliation":[{"name":"Haemophilia Center Rhine Main, HZRM, M\u00f6rfelden-Walldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the \u2018St\u00e4ndige Kommission H\u00e4mophilie\u2019 (Haemophilia board) of the German, Swiss Austrian Society for Thrombosis Haemostasis Research (GTH)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"T Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"21","key":"ref2","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"M Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"ref3","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"N Uchida","year":"2016","journal-title":"Blood"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumabprophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumabprophylaxis in patients who have hemophiliaA without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"ref6","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"P J Lenting","year":"2017","journal-title":"Blood"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"F Hasson","year":"2000","journal-title":"J Adv Nurs"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"S W Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"S 01","key":"ref10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2018-99-118153","article-title":"Emicizumabprophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study","volume":"132","author":"G Young","year":"2018","journal-title":"Blood"},{"issue":"S 01","key":"ref11","first-page":"1071","article-title":"Emicizumabprophylaxis in adolescent\/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study","volume":"130","author":"M E Mancuso","year":"2017","journal-title":"Blood"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"G G Levy","year":"2019","journal-title":"J ThrombHaemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"Surgical procedures in persons with haemophilia A (PWHA) without inhibitors receiving emicizumab \u2013 experience from the HAVEN 3 study","volume":"25","author":"E Santagostino","year":"2019","journal-title":"Haemophilia"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Y Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"S 01","key":"ref19","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2018-99-114355","article-title":"Pre-analysis for hemostatic effect of bypassing agents in hemophilia a patients with inhibitors under the emicizumab prophylaxis by global assays","volume":"132","author":"S Furukawa","year":"2018","journal-title":"Blood"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.3324\/haematol.2018.215129","article-title":"Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement","volume":"104","author":"E Santagostino","year":"2019","journal-title":"Haematologica"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"R Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V130.Suppl_1.89.89","article-title":"Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)","volume":"130","author":"R Kruse-Jarres","year":"2017","journal-title":"Blood"},{"issue":"S 01","key":"ref23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood-2018-99-115089","article-title":"Maintaining perioperative hemostasis in patients with severe hemophiliaA and inhibitors receiving emicizumab prophylaxis","volume":"132","author":"K L Zimowski","year":"2018","journal-title":"Blood"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/bloodadvances.2019000228","article-title":"Emicizumab use in major orthopedic surgery","volume":"3","author":"C D Seaman","year":"2019","journal-title":"Blood Adv"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2040620719860025","DOI":"10.1177\/2040620719860025","article-title":"Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays","volume":"10","author":"H Kizilocak","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"S 01","key":"ref27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000056717","article-title":"Induction of immune tolerance in haemophilia A inhibitor patients by the \u2018Bonn Protocol\u2019: predictive parameter for therapy duration and outcome","volume":"77","author":"J Oldenburg","year":"1999","journal-title":"Vox Sang"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2516.1995.tb00036.x","article-title":"Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up","volume":"1","author":"W Kreuz","year":"1995","journal-title":"Haemophilia"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2516.1999.00311.x","article-title":"German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies","volume":"5","author":"H H Brackmann","year":"1999","journal-title":"Haemophilia"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder","volume":"2","author":"H H Brackmann","year":"1977","journal-title":"Lancet"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"P W Collins","year":"2018","journal-title":"Haemophilia"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/17474086.2018.1521718","article-title":"The importance of inhibitor eradication in clinically complicated hemophilia A patients","volume":"11","author":"J Oldenburg","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000495454","article-title":"Inhibitors: a need for eradication?","volume":"141","author":"E Santagostino","year":"2019","journal-title":"Acta Haematol"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"G Batsuli","year":"2019","journal-title":"Haemophilia"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"M Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"e27886","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort","volume":"66","author":"A A Barg","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"07","key":"ref38","first-page":"1084","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"J I Adamkewicz","year":"2019","journal-title":"ThrombHaemost"},{"issue":"09","key":"ref39","first-page":"1384","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"J M\u00fcller","year":"2019","journal-title":"ThrombHaemost"},{"key":"ref40","first-page":"98","article-title":"Monitoring of emicizumab (ACE910): comparison between clotting and chromogenic assay","volume":"25","author":"H T\u00fcrkantoz","year":"2019","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2018-99-118492","article-title":"Immunogenicity of emicizumab in people with hemophiliaA (PwHA): results from the HAVEN 1\u20134 studies","volume":"132","author":"I Paz-Priel","year":"2018","journal-title":"Blood"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1127-6476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:21:15Z","timestamp":1696288875000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1127-6476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":35,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2020,12,29]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1127-6476","relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}